Onconova Therapeutics has dosed the first patient in its Phase I/IIa clinical trial of narazaciclib combined with letrozole to treat endometrial cancer.
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa., May 11,...
MSN Lab Generic Letrozole: Ribociclib Succinate Receives Tentative Approval in the U.S.A
NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). In addition, the Company reported its third quarter 2022 financial results and provided a business update.
After a median follow-up of seven and a half years, Ibrance, used alongside Novartis’ hormone therapy Femara, failed to extend the lives of those breast cancer patients compared with Femara alone, according to data presented at the 2022 American Society of Clinical Oncology annual meeting.
Newly published data reveals that Novartis‘ Kisqali (ribociclib) plus letrozole demonstrated a statistically significant improvement in overall survival in hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in the Phase III Monaleesa-2 trial .
Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. These data will be presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 on September 19 (#LBA17).
Beijing Yiling`s Generic Letrozole Receives Approval in US
Enforcement Report - Week of May 16, 2018
Lilly's drug achieved a median progression-free survival (PFS) of 16.4 months versus 9.3 months in the control arm, and the objective response rate (ORR) was 48% and 21%, respectively. Lead investigator George Sledge of Stanford University said: “This is believed to be the highest response ever recorded in this patient population in a large-scale trial.”